HELIOS Klinikum Emil von Behring GmbH — Clinical Trial Site

41 Registered trials

17 Currently recruiting

Organisation

HELIOS Klinikum Emil von Behring GmbH

Location

Berlin, Germany

Identifier

ORG-100032142

Address

Walterhoeferstrasse 11, Zehlendorf, 14165, Germany

Departments

2611: Klinikum Emil von Behring
Clinic for Pneumology
Haus Q - Klinische Studien
Helios Klinikum Emil von Behring
HELIOS Klinikum Emil von Behring GmbH
Klinik f. Onkologie u. Hämatologie
Klinik für Hämatologie und Onkologie
Klinik für Interdisziplinäre Onkolo-gie
Klinik für Plastische und Ästhetische Chirurgie
Klinik für Pneumologie
Klinik für Pneumologie - Lungenklinik Heckeshorn
Klinik für Pneumologie (Haus Q)
Klinik für Pneumologie Lungenklinik Heckeshorn
Klinik für Pneumologie, Lungenklinik Heckeshorn
Lungenklinik Heckesborn
Lungenklinik Heckeshorn
Lungenklinik Heckeshorn, Klinik für Pneumologie
Lungenklink Heckshorn
n.a.
N/A
Pneumologie Onkologie u.Infektiologie
Pneumology

Clinical trials at this site (41)

Search interface

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Pending

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5
A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending

2025-523586-18-00 Non-Small Cell Lung Cancer 5
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Progressive Pulmonary Fibrosis 5 2024-07-15
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Idiopathic pulmonary fibrosis 5 2024-06-24
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N… Recruiting

2023-503920-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2024-01-02
A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting

2024-511362-37-00 Non squamous non-small cell lung cancer (NSCLC) 5 2026-02-18
A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting

2024-517553-26-00 Advanced ALK-positive non-small cell lung cancer (NSCLC 5 2025-11-12
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Previously Untreated Advanced or Metastatic Non-Squamou 5 2025-10-28
– IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici… Recruiting

2024-519929-38-00 Metastatic Colorectal Cancer without liver metastases 4 2025-10-27
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
Inhalation therapy in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept … Recruiting

2023-509277-22-00 Bronchiectasis 4 2022-06-22
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trif… Recruiting

2024-513723-16-00 metastatic colorectal cancer 4 2021-10-21
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo… Recruiting

2024-518077-34-00 locally advanced rectal cancer 5 2020-09-30
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended

2024-516051-40-00 Small Cell Lung Cancer (SCLC) 4 2025-06-10
CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS Ended

2024-512720-11-00 chronic venous ulcers (CVU) 5 2025-01-16
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26